This clinical trial investigates the effectiveness of a 50mcg/day transdermal estradiol patch in treating anorexia nervosa (AN). Building on preliminary evidence suggesting estradiol's role in mood, cognition, bone health, and appetite regulation, this study aims to explore its therapeutic potential in addressing the multifaceted symptoms of AN.

Trial Objective:

1. Assess the impact of the transdermal estradiol patch on improving psychological symptoms of AN from baseline to the end of treatment (12 weeks).
2. Evaluate the effectiveness of the estradiol patch in stabilising and increasing body mass from baseline to the end of treatment.

Eligibility Criteria:
Current diagnosis of AN (can be assessed at screening if not formally diagnosed)\
Age 16 or older
Female

Trial Design & Procedure:
This clinical trial will enrol 50 participants who will be randomly assigned to receive either the estradiol patch (50mcg/day) or a placebo, for a duration of 12 weeks. Participants’ eating disorder symptoms and broader psychological symptoms will be measured every 4 weeks.

Potential Benefits & Positive Outcomes:
Demonstrate the effectiveness of estradiol in improving psychological symptoms and body mass in AN.
Provide insights into estradiol's role in mood and cognition, and its regulatory effects on appetite.
Offer a novel, potentially more effective treatment option for AN, addressing the urgent need for innovative therapeutic strategies in this challenging and often chronic condition.

To find out more about participating in a Li-THRED Treatment Trial
Email us: THRED@monash.edu
Or phone us: (03) 9076 9802